Fundz

AAVantgarde secures $141m Series B funding to advance its gene therapies for inherited retinal diseases.

PRIVATENov 03, 2025

Amount Raised

$141 Million

Round Type

Series B

MilanBiotechnologyHealth CareGeneticsTherapeuticsresearch

Description

AAVantgarde has secured $141 million in Series B funding focused on advancing its clinical programs for inherited retinal diseases. This financing will support the development of AAVB-039 for Stargardt disease and AAVB-081 for Usher 1B. The therapies aim to treat the root causes of these conditions. CEO Dr Natalia Misciattelli emphasized the validation of their team and science through this investment.

Company Information

Company

AAVantgarde Bio

Location

Milan, Lombardy, Italy

About

AAVantgarde is a clinical-stage, international biotechnology company (headquartered in Italy) that has developed two proprietary adeno-associated viral (AAV) vector platforms to address the DNA cargo capacity limitations of AAV vectors

Fundz sees it the moment AAVantgarde Bio raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.

Related People

5 contacts
Verified contactsMalcolm H., Vice President Project Management and I… hidden hiddenSee plans and pricing
Predictive Intelligence
Strategic

ML-powered predictions for AAVantgarde Bio's next move

See what Strategic adds

Funding Insights

What this usually means
Timeline to next round
Series B companies typically work for 15-20 months before raising new capital
Growth expectations
Series B companies are expected to scale rapidly and expand market reach

AAVantgarde Bio raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.

145 of these a day, filtered to the companies you pick, with the decision-maker attached.

5 screens from a live account. No signup.

Fundz is a real-time business intelligence platform powered by agentic AI that proactively delivers personalized daily signals, including funding rounds, executive changes, M&A activity, 13F institutional filings, SEC 8-K events, investor activity, and website modifications, based on each user's watchlist and ICP. A trusted data source at firms such as BlackRock, Oracle, Kleiner Perkins, LinkedIn, HubSpot, and Cloudflare, Fundz democratizes the institutional-grade intelligence that previously required a PitchBook or Bloomberg terminal. Features include FundzWatch™ for automated website change detection, Daily Briefing for AI-powered daily briefings, and unified cross-signal alerts across 281,000+ organizations. Developers and data teams can access these signals programmatically via the Fundz Funding Data API, with transparent published pricing.